CD30 InhibitorChemical ConsultantsUpdated on May 30, 2019 View more like this | Visit SHIRLEY, NY | Contact BOCSCI INC |
CD30 and Diseases
CD30 overexpression in HL and ALCL may be a potential target for antibody targeting therapy. Antibody targeting therapy has a significant breakthrough in the treatment of Hodgkin's lymphoma and anaplastic large cell lymphoma. It has changed the traditional treatment methods and significantly increased the survival rate of CD30 positive patients. With the development of genetic engineering technology, the emergence of novel antibody drugs and vaccines for CD30 targets, and the in-depth study of the mechanism of CD30 and tumorigenesis, will greatly change the treatment status of CD30 positive tumors. It brings light to more patients.
CD30 overexpression in HL and ALCL may be a potential target for antibody targeting therapy. Antibody targeting therapy has a significant breakthrough in the treatment of Hodgkin's lymphoma and anaplastic large cell lymphoma. It has changed the traditional treatment methods and significantly increased the survival rate of CD30 positive patients. With the development of genetic engineering technology, the emergence of novel antibody drugs and vaccines for CD30 targets, and the in-depth study of the mechanism of CD30 and tumorigenesis, will greatly change the treatment status of CD30 positive tumors. It brings light to more patients.
